Hua Medicine (HKSE:02552) ROCE % : -19.48% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Hua Medicine ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hua Medicine's annualized ROCE % for the quarter that ended in Jun. 2024 was -19.48%.

Hua Medicine ROCE % Historical Data

The historical data trend for Hua Medicine's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hua Medicine ROCE % Chart

Hua Medicine Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-32.80

-35.87

-34.72

-22.12

-16.76

Hua Medicine Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial											-26.63	-23.10	-18.84	-19.80	-19.48

Hua Medicine ROCE % Calculation

Hua Medicine's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-222.395	/	( ( (1252.392 - 210.373)	+	(1887.177 - 275.669) )	/ 2 )
	=	-222.395	/	( (1042.019	+	1611.508)	/ 2 )
	=	-222.395	/	1326.7635
	=	-16.76 %

Hua Medicine's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-297.904	/	( ( (1887.177 - 275.669)	+	(1781.448 - 334.887) )	/ 2 )
	=	-297.904	/	( ( 1611.508	+	1446.561 )	/ 2 )
	=	-297.904	/	1529.0345
	=	-19.48 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Hua Medicine (HKSE:02552) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hua Medicine ROCE % Related Terms

Thank you for viewing the detailed overview of Hua Medicine's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hua Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hua Medicine (HKSE:02552) » Definitions » ROCE %

Traded in Other Exchanges

HUMDF:USA

Address

Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203

Website

https://www.huamedicine.com

Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes. The group majorly operates in the PRC.

Executives

Hlyy Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
Hong Jane Xingfang	2202 Interest of your spouse
Chen Li	2101 Beneficial owner
Wuxi Pharmatech Investments (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Investment Holdings (cayman) Inc.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Fund I General Partner L.p.	2201 Interest of corporation controlled by you
Wuxi Pharmatech Healthcare Fund I L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.	2201 Interest of corporation controlled by you
Wuxi Apptec International Holdings Limited	2201 Interest of corporation controlled by you
Nelsen Robert Taylor	2101 Beneficial owner
Venrock Management V, Llc	2102 Investment manager
Harvest Yuanxiang (cayman) Limited	2101 Beneficial owner
Arch Venture Fund Vii, L.p.	2101 Beneficial owner

Hua Medicine Headlines

No Headlines